"What we are showing is that the rates of transmitted drug-resistant HIV in the low- and middle-income countries most affected by HIV have increased modestly. The rate of increase in sub-Saharan Africa has been low, and an increase has not been detected in south Asia and Southeast Asia. That's good news," said Robert Shafer, M.D., professor of medicine at Stanford and principal investigator on the study.
08 April 2015 | Genetic Engineering & Biotechnology News
In general, the integrase ihibitors raltegravir and dolutegravir have potent anti-HIV activity and have relatively few interactions with other drugs. However in clinical trials of raltegravir, strains of HIV that can resist raltegravir have emerged in up to 60% of heavily treatment-experienced people, and up to 8% of participants who have never taken HIV drugs before. A study in France of patients who had virologial failure to HIV therapy while taking raltegravir has found that 61% had HIV that was still susceptible to all integrase inhibitors. In cases where HIV was resistant to raltegravir, 14% were also resistant to dolutegravir.
21 January 2015 | CATIE
The new anti-HIV integrase inhibitor dolutegravir is a highly potent drug. Alain Lafeuillade, a clinical researcher for 20 years in HIV disease, observed that Dolutegravir is highly effective alone in patients without integrase resistance. "Plasma viral load remained undetectable in my patients, and proviral HIV DNA in cells remained stable with only 50 mg 2 to 3 times a week," he said. He is proposing a low-dose dolutegravir monotherapy trial.
21 January 2015 | MMD Newswire
For the first time, a study has shown that, although rare, resistance to Truvada can develop if someone contracts HIV while taking the drug as PrEP.
16 January 2015 | AIDSMeds
The stark figures, published on Thursday, and believed to be the first to quantify the potential impact of antimicrobial resistance (AMR) – drug-resistant infections or superbugs – will be used to make the case to global leaders that urgent action is needed. To put the figures in context there are currently 8.2 million deaths a year from cancer and annual global GDP stands at $70tn to $75tn, with the UK figure around $3tn.
11 December 2014 | The Guardian
TB treatment must be shorter, simpler, less toxic, and more tolerable and affordable. Activists can contribute to the development and uptake of improved TB treatment by calling attention to research, quality of medications, and access priorities.
04 June 2014 | TAG
More than 17% of antiretroviral-naive men who have sex with men (MSM) in a large US study carried antiretroviral-resistant virus, according to a nationwide analysis by the Centers for Disease Control and Prevention (CDC)]. MSM under 30 years old had close to a 19% prevalence of transmitted resistant HIV.
06 March 2014 | NATAP
As is plainly obvious to anyone doing HIV care, the incidence of new patients with the sort of HIV drug resistance for which the test was developed has plummeted. There simply aren't many new patients out there who have multiple mutations, especially in the PI-drug class, and who will need the computational black-box firepower provided by a vircoTYPE.
27 November 2013 | The BodyPRO
An exclusive worldwide licensing agreement has been signed for the rights to a series of diagnostic tests to determine drug resistance and co-receptor tropism in human immunodeficiency virus (HIV). The tests will be used by physicians and researchers to monitor the success of anti-HIV treatment by determining drug resistance and the ability of the virus to infect different cells within the patient. The HIV assays also can be used by academic and corporate researchers to develop novel strategies to block HIV replication.
03 July 2013 | University Hospitals Case Medical Center
Wide HIV testing and early treatment woul lower HIV transmission, AIDS and death rates, but double the rate of multidrug resistance (MDR) to antiretrovirals.
26 March 2013 | AIDSMeds